Upcoming Events
Log In
Pricing
Free Trial

AML

HIDE
PrevNext

0:01

Dr. P. talking renal masses here.

0:01

3 00:00:01,560 --> 00:00:03,150

0:03

I've got before you on the left an

0:05

out of phase GRE with a short TE.

0:09

Look at the India ink effect, this

0:11

dark line between the kidney and the

0:13

surrounding fat, a fat-water interface.

0:16

An in-phase GRE with a slightly

0:17

longer TE, and then a T2 fast spin echo without supression.

0:23

This is a 65-year-old lady who two years ago

0:26

had a renal mass in the left posterior kidney.

0:29

She has multiple renal masses, many of

0:31

which are cysts, some hemorrhagic cysts.

0:34

And then, two years later, while this lesion

0:36

is being followed, it goes from one to two

0:38

centimeters, namely this one in the back.

0:41

So when we look at the in-phase GRE, the lesion is

0:44

slightly hyperintense to the rest of the kidney.

0:47

Not as much as this lesion is.

0:49

But when we go out of phase, that lesion does not

0:52

drop out, hemorrhagic cyst; this lesion does drop

0:57

out, and suggests the presence of microscopic fat.

1:01

Now where do we see microscopic fat in the kidney?

1:04

We see microscopic fat in AML or angiomyolipoma,

1:08

some renal cell carcinomas, and even in Wilms tumors.

1:12

Let's talk briefly about AMLs, because AML,

1:15

angiomyolipoma, not acute myelogenous leukemia.

1:18

AML is the introductory topic for this vignette.

1:23

Now on the right-hand side of

1:26

your screen is a T2 spin echo.

1:29

Many of the cysts are nice and

1:30

bright and round and homogeneous.

1:32

This lesion in the back of

1:34

the left kidney, not so much.

1:36

So we have a problem.

1:38

So a couple of questions to be answered.

1:42

First, what is it?

1:44

Second, is it aggressive or non-aggressive?

1:46

And how are we gonna, how are we gonna do that on MRI?

1:50

Uh, there are a few tools we have in our toolbox.

1:54

We've got diffusion-weighted MR, although that is

1:57

not incredibly reliable in making that distinction.

2:00

If it heavily diffusion restricts, that might push

2:02

us one way, but it's not pathognomonic of malignancy.

2:06

And we've got hypervascularity.

2:08

Hypervascularity could occur, and does

2:11

occur, in angiomyolipomas, but it also

2:14

occurs in many renal cell carcinomas.

2:18

Let's touch on angiomyolipoma for a minute.

2:22

As a mass, I'm going to bring down the

2:23

diffusion image and show you that the,

2:26

the lesion is weakly diffusion restricted.

2:29

Angiomyolipoma occurs most frequently

2:33

in the fourth through sixth decades of life with

2:37

increased prevalence in women.

2:39

This is a woman.

2:41

She is 65 years of age, so pretty close

2:44

to the peak age group.

2:47

These are now regarded as part of the

2:49

family of perivascular epithelioid or

2:52

epithelioid cell tumors, also known as PEComas.

2:56

And it comprises a heterogeneous group of tumors with

3:00

variable pathologic imaging and clinical features.

3:04

AML is typically composed of variable

3:06

amounts of dysmorphic blood vessels, which

3:09

is why it's hypervascular, smooth muscle

3:12

components, and mature adipose tissue.

3:15

But not all of them have macroscopic fat.

3:17

Some have microscopic fat, and most of

3:20

these are sporadic, 80% of the time.

3:23

But, the remaining 20% are associated with

3:27

tuberous sclerosis complex, and may be associated

3:30

with lymphangioleiomyomatosis, and here we've got an

3:35

indeterminate lesion that requires further definition.

3:38

Now, one of the first things I might do here is

3:41

give contrast and look at the arterial phase, the

3:45

portal venous phase, and the nephrogenic phase.

3:48

So I'll look at 30 to 60 seconds,

3:50

60 to 90 seconds and so on.

3:52

But let's go early.

3:53

Let's go around 45 or 50 seconds, maybe

3:56

a little longer than I would have liked.

3:58

But we do have a nice crisp

4:00

arterial enhancement pattern.

4:01

And our lesion is lighting up

4:03

and lighting up pretty briskly.

4:05

So that doesn't tell us between the two which it is.

4:09

But it does tell us that it is not a hemorrhagic cyst.

4:13

You can see our hemorrhagic cyst

4:15

did not invert or suppress when we went out of phase,

4:20

like a micro or macroscopic

4:22

fat-containing lesion might do.

4:24

Our hemorrhagic cyst stayed nice and bright.

4:27

Our hemorrhagic cyst is cold.

4:29

It has no contrast enhancement.

4:31

Our lesion, it's hot.

4:33

It's hypervascular.

4:34

If we go all the way down the road to something

4:37

a lot later, and say the, uh, the delayed phase,

4:40

two, three, four minutes, our mass is still

4:44

hypervascular, although it's washing out a little bit.

4:46

But clearly, vascular mass, complex

4:50

character, has some fat in it.

4:53

Now we've got a job to do.

4:54

Is it AML or renal cell carcinoma?

4:57

I suggest you move on to the next vignette.

5:00

Dr. P out.

Report

Faculty

Stephen J Pomeranz, MD

Chief Medical Officer, ProScan Imaging. Founder, MRI Online

ProScan Imaging

Tags

Vascular

Non-infectious Inflammatory

Neoplastic

MRI

Kidneys

Genitourinary (GU)

Body

© 2024 Medality. All Rights Reserved.

Contact UsTerms of UsePrivacy Policy